Bacil Pharma Limited has scheduled a meeting of its Board of Directors for Tuesday, August 25, 2026. The company disclosed the intimation pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015.

The board will consider key resolutions during the session. The primary agenda item involves the discussion on the appointment of directors. The meeting will also address any other business with the permission of the Chairperson.

The intimation was issued on August 17, 2026, by Ms. Chaitali Kalpataru Shah, Director & CFO of the company. She directed the communication to the Listing Department of BSE Limited for record-keeping purposes.

Agenda Details

The board meeting focuses on corporate governance updates rather than financial results. The specific items for consideration include:

• Discussion on the appointment of directors.
• Any other business permitted by the Chairperson.

No financial data, revenue figures, or profit metrics were disclosed in this filing, as it serves as a procedural notice for an upcoming governance event.

Bacil Pharma Limited reported a net loss of ₹1.61 lakh for the quarter ended June 30, 2026, marking a significant deterioration from the profit of ₹62.16 lakh recorded in the previous quarter. The company’s total revenue fell to ₹8.91 lakh from ₹11.34 lakh, driven by a decline in other income. This shift highlights volatility in the firm’s earnings structure, where non-operating items heavily influence the bottom line.

The Board of Directors approved the unaudited financial results on August 12, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Sarang Shivajirao Chavan and Associates, in accordance with Standard on Review Engagements (SRE) 2410. The financial statements were prepared in compliance with Indian Accounting Standards (Ind AS).

Financial Performance Overview

The company generated no revenue from operations during the quarter, relying entirely on other income. Total expenses stood at ₹2.27 lakh, comprising employee benefits expense of ₹0.72 lakh and other expenses of ₹1.55 lakh. Before tax, the company recorded a profit of ₹6.64 lakh. However, a deferred tax expense of ₹8.25 lakh pushed the post-tax result into negative territory.

What the Numbers Show

The primary driver of the quarterly loss was the deferred tax expense of ₹8.25 lakh, which exceeded the pre-tax profit of ₹6.64 lakh. In contrast, the previous quarter saw a much higher deferred tax charge of ₹58.27 lakh against a lower pre-tax profit of ₹3.89 lakh, yet it still resulted in a net profit due to other comprehensive income adjustments or timing differences not fully detailed in the summary figures. The current quarter’s basic earnings per share (EPS) stood at ₹0.22, down from ₹0.44 in the preceding quarter. The company’s paid-up equity share capital remained unchanged at ₹1,397.03 lakh.

The limited review report confirmed that the unaudited financial results are free of material misstatement based on the procedures performed. The company operates in a single reportable segment: primary pharmaceutical business.